Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Rev. colomb. nefrol. (En línea) ; 6(2): 122-129, jul.-dic. 2019. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1093036

ABSTRACT

Resumen Introducción: el lupus eritematoso sistémico (LES) presenta diferentes manifestaciones clínicas, un de estas es la nefropatia lúpica (NL), que se asocia con progresión a enfermedad renal crónica (ERC) avanzada y mortalidad. Objetivo: determinación de las características clínicas y epidemiológicas de la NL en Santander. Métodos: estudio observacional descriptivo tipo serie de casos en pacientes con NL evaluados por primera vez, entre enero de 2017 a enero 2018, en consulta de nefroprevención. Según criterios de inclusión y exclusión se definieron variables cualitativas y cuantitativas. Se revisaron historias clínicas y el análisis de datos se realizó por medio de SPSS®. Resultados: se estudiaron 14 pacientes (85 % mujeres), la edad promedio de diagnóstico de NL fue de 36 años, con ERC 1 y 2 (72 %) y con proteinuria A3 (85 %). Se obtuvo biopsia renal en 64 %, con resultado concluyente en el 50 %, la clase histopatológica IV de NL fue la más común. La terapia de mantenimiento más frecuente fue corticoide en monoterapia (36 %), seguido de la combinación de corticoide y micofenolato (29 %). Conclusión: la NL predomina en mujeres jóvenes, en estadios tempranos de ERC con altos grados de proteinuria, por lo que se debe realizar una evaluación minuciosa en búsqueda de NL a todos los pacientes con LES, mediante programas de detección y seguimiento nefrológico temprano. El grado histopatológico IV fue el más frecuente, similar a lo reportado en Latinoamérica. Existen dificultades administrativas y técnicas en la toma de biopsias renales, se debe hacer énfasis en la necesidad de su realización, por su primordial importancia para definir el tratamiento.


Abstract Introduction: Systemic Lupus Erythematosus (SLE) has different clinical manifestations, being very relevant lupus nephropathy (NL) because is associated with progression to advanced chronic kidney disease (CKD) and mortality. Objective: Determination of the clinical and epidemiological characteristics of the NL in Santander. Methods: A descriptive observational study of a series of cases in patients with NL diagnosis, evaluated between January 2017 and 2018 for the first time in a nephroprotection consultation. Qualitative and quantitative variables are defined according to the inclusion and exclusion criteria. Electronic medical records were reviewed, and data analysis was performed through SPSS®. Results: 14 patients (85% women) were studied. The average age of diagnosis of NL was 36 years, mostly with stages of CKD 1 and 2 (72%) with proteinuria A3 (85%).Biopsy renal was performed in the 64%, a conclusive result in the 50%, being the histopathological grade IV of NL the most common. The most frequent maintenance therapy was corticosteroid alone (35.7%), followed by the combination of corticosteroid and mycophenolate (28.5%). Conclusion: NL predominates in young women, and presenting in early stages of CKD, with high degrees of proteinuria, so a thorough evaluation should be performed in search of NL in all patients with SLE through early nephrological screening and monitoring programs. The histopathological grade IV found is like that reported in Latin America. There are administrative and technical difficulties in the performance of renal biopsies, emphasis should be placed on the realization of this procedure because it takes a primary role in defining the treatment.


Subject(s)
Humans , Male , Female , Biopsy , Kidney Diseases , Lupus Erythematosus, Systemic , Proteinuria , Colombia , Renal Insufficiency, Chronic
2.
Herrera-Molina, Emilio; González, Nancy Yomayusa; Low-Padilla, Eduardo; Oliveros-Velásquez, Juan David; Mendivelso-Duarte, Fredy; Gómez-Gómez, Olga Victoria; Castillo, Ana María; Barrero-Garzón, Liliana Isabel; Álvarez-Moreno, Carlos Arturo; Moscoso-Martínez, Ernesto Augusto; Ruíz-Blanco, Pilar Cristin; Luna-Ríos, Joaquín Gustavo; Ortiz, Natasha; Herrera, Emiliano Mauricio; Guevara-Santamaría, Fabián; Moreno-Gómez, Jairo Enrique; Cárdenas-Ramírez, Héctor Mauricio; González-González, Camilo Alberto; Jannauth, María José; Patiño-Pérez, Adulkarin; Pinto, Diego Alejandro; Acevedo, Juan Ramon; Torres, Rodolfo Eduardo; Montero, Jairo Camilo; Acevedo, Andrés David; Caceres, Ximena Adriana; Acuña-Olmos, Jairo; Arias, Carlos Andrés; Medardo-Rozo, José; Castellanos-Parada, Jeffrey; López-Miranda, Ángelo Mauricio; Pinzón-Serrano, Estefanía; Rincón-Sierra, Oswaldo; Isaza-Ruget, Mario; Suárez-Ramos, María del Pilar; Vargas-Rodríguez, Johanna; Mejia-Gaviria, Natalia; Moreno-Marín, Sandra Yadira; García-Guarín, Bibiana María; Cárdenas, Martha Lucía; Chavarro, Luis Fernando; Ronderos-Bernal, Camila; Rico-Landazabal, Arturo; Coronado-Daza, Jorge Antonio; Alfaro-Tejeda, Mercedes Teresa; Yama-Mosquera, Erica; Hernández-Sierra, Astrid Patricia; Restrepo-Valencia, César Augusto; Arango-Álvarez, Javier; Rosero-Olarte, Francisco Oscar Fernando; Medina-Orjuela, Adriana; Robayo-García, Adriana; Carballo-Zarate, Virgil; Rodríguez-Sánchez, Martha Patricia; Bernal, Dora P.; Jaramillo, Laura; Baquero-Rodríguez, Richard; Mejía-Gaviria, Natalia; Aroca, Gustavo.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1535986

ABSTRACT

está disponible en el texto completo


The exponential increase in the request for laboratory tests of 25-Hydroxyvitamin D or [25 (OH) D has ignited the alarms and generated a strong call for attention, since it may reflect deficiencies in the standardization of clinical practice and in the use non-systematic scientific evidence for decision-making in real life, which allows to analyze the indications of the test, its frequency, interpretation and even to assess the impact for health systems, especially when contrasted with the minimum or almost. No effects of the strategy of screening or supplying indiscriminately to the general population, without considering a comprehensive clinical assessment of risks and needs of people. From a purely public health impact point of view, the consequence of massive and unspecified requests is affecting most of the health systems and institutions at the global level. The primary studies that determined average population intake values have been widely used in the formulation of recommendations in Clinical Practice Guidelines, but unfortunately misinterpreted as cut points to diagnose disease and allow the exaggerated prescription of nutritional substitution. The coefficient of variation in routine tests to measure blood levels of 25 (OH) D is high (28%), decreasing the overall accuracy of the test and simultaneously, increasing both the falsely high and falsely low values. The most recent scientific evidence analyzes and seriously questions the usefulness and the real effect of the massive and indiscriminate practice of prescribing vitamin D without an exhaustive risk analysis. The available evidence is insufficient to recommend a general substitution of vitamin D to prevent fractures, falls, changes in bone mineral density, incidence of cardiovascular diseases, cerebrovascular disease, neoplasms and also to modify the growth curve of mothers' children. They received vitamin D as a substitute during pregnancy. The recommendations presented in the document are based on the critical analysis of current evidence and the principles of good clinical practice and invite to consider a rational use of 25 (OH) D tests in the context of a clinical practice focused on people and a comprehensive assessment of needs and risks. The principles of good practice suggest that clinicians may be able to justify that the results of the 25 (OH) D test strongly influence and define clinical practice and modify the outcomes that interest people and impact their health and wellness. Currently there is no clarity on how to interpret the results, and the relationship between symptoms and 25 (OH) D levels, which may not be consistent with the high prevalence of vitamin D deficiency reported. For this reason, it is suggested to review the rationale of the request for tests for systematic monitoring of levels of 25 (OH) D or in all cases where substitution is performed. Consider the use of 25 (OH) D tests within the comprehensive evaluation of people with suspicion or confirmation of the following conditions: rickets, osteomalacia, osteoporosis, hyper or hypoparathyroidism, malabsorption syndromes, sarcopenia, metabolic bone disease.

SELECTION OF CITATIONS
SEARCH DETAIL